source
- Sionna Therapeutics cuts 46% of staff after cystic fibrosis trial missSionna Therapeutics announced it will lay off roughly half of its employees as it reassesses its strategy following a recent setback in its cystic fibrosis program. The company’s lead candidate, S…
- FDA approves first radioligand generic, pitting Curium against Novartis' LutatheraThe U.S. Food and Drug Administration has granted approval to Curium’s radioligand product, the first generic in this therapeutic class. The approved drug is a direct equivalent of Novartis’ Lutat…